Humacyte (HUMA) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Technology platform and manufacturing

• Developed universally implantable, regenerative human tissues using human cells and proprietary bioreactor systems, producing decellularized arteries that avoid immunologic rejection.

• Commercial-scale manufacturing in place since June 2021, with modular incubator systems (LUNA200) capable of producing 1,000 arteries per unit per year.

• Engineered arteries are acellular, shelf-stable for 18 months, and repopulate with patient cells post-implantation, becoming living tissue.

• Over 600 patients treated across multiple indications with no immunologic rejection and high durability observed up to 10 years.

• Current manufacturing capacity is 8,000 vessels per year, scalable to 40,000 vessels annually.

Clinical trial results and indications

• Lead indication is vascular trauma, with positive phase II/III trial results showing improved limb salvage and lower infection rates compared to synthetic grafts.

• Real-world evidence from Ukrainian warfighters supported efficacy and ease of use, with training conducted remotely.

• Combined civilian and military data showed significant improvements in patency, infection, and amputation rates versus benchmarks.

• Phase III trial in dialysis access (V007) demonstrated superior usability (81% vs. 66%) and patency (68% vs. 62%) over fistula at 12 months.

• Subgroup analyses indicate particularly strong results in high-risk populations (women, obese, diabetics), supporting both clinical and economic value.

Regulatory and commercialization progress

• Biologics License Application (BLA) submitted December last year; FDA review ongoing with no negative signals, initial PDUFA date delayed for further review.

• Commercial launch preparations underway, with half of the U.S. sales force hired and trained, targeting 200 Level I trauma centers.

• Collaboration with Fresenius for European commercialization across trauma, dialysis, and PAD indications.

• Health economic arguments emphasize cost savings from reduced amputations and durable access, especially in high-cost patient segments.

• Anticipated price point for the vessel is $25,000–$30,000, with sufficient manufacturing capacity for initial commercialization.